Hormonal
Obeticholic acid (25 mg/day) improves liver fibrosis in patients with MASH and stage 2-3 fibrosis, but does not significantly resolve MASH activity compared to placebo.
Obeticholic acid (25 mg daily) can significantly improve liver scarring (fibrosis) in patients with advanced MASH, but it does not reliably eliminate the inflammation (MASH) itself. The main barrier is itching (pruritus). This treatment is for specific high-risk patients, not general MASLD.
In the group that received 25 mg of OCA, 23% of patients showed improvement... it was concluded that treatment with 25 mg of OCA led to a significant improvement in fibrosis and a reduction in activity in patients with MASH... the degree of resolution of MASH was not statistically significantly different in patients who received a placebo compared to those who received OCA.
Why this rating
Based on multicenter, randomized, double-blind, placebo-controlled trials (REGENERATE, FLINT).
Source
New Therapeutic Approaches for the Treatment of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Increased Cardiovascular Risk
Marija Branković et al. · Diagnostics · 2024
DOI 10.3390/diagnostics14020229
More from this paper
- Pioglitazone (PPAR-gamma agonist) resolves MASH and reduces fibrosis stage, but its use is limited by adverse effects including fluid retention, weight gain, and osteopenia.Good
- GLP-1 agonists (Semaglutide, Liraglutide) and dual GIP/GLP-1 agonists (Tirzepatide) are potential pharmacotherapies for MASLD/MASH due to their metabolic effects and ability to induce weight loss.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →